European journal of applied physiology · 2026
Caffeinated chewing gum improves military performances in special forces soldiers.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shiu Yi-Jie, Chen Che-Hsiu, Lin Hung-Yu, Yang Chia-Cheng, Yen Chi-Wen, Chang Han-Yuan, Chen Hsuan-Ta, Chiu Chih-Hui
Аннотация
PURPOSE: The purpose of this study was to investigate the effects of caffeinated chewing gum on the cognitive tasks, strength and military performance of tier 1 special forces soldiers in Taiwan.
METHODS: Sixteen male serving special forces soldiers (age: 34 ± 7 years; height: 172 ± 4 cm; BMI: 25.4 ± 2.7 kg/m²) completed the caffeinated chewing gum (CAF) trial and the placebo (PL) trial using a randomised crossover experimental design. After chewing the caffeinated chewing gum containing 3 mg·kg- 1 of caffeine (CAF trial) or placebo gum (PL trial), participants completed the cognitive tasks, grip strength, weighted vertical jump and the special forces military performance tests which included rapid-fire test and close-quarters battle (CQB) tests. Before, during, and after the experiment, the heart rate variability and salivary α-amylase were collected.
RESULTS: Grip strength (increase 4.4 ± 7.1 kg; P = 0.037), weighted vertical jump height (increase 1.3 ± 2.1 cm; P = 0.032), cognitive tasks (simple response times, stroop task and visual search reaction time in 20 items) (P < 0.05), shooting scored in rapid-fire test (increase 1.0 ± 2.1 points; P = 0.030), the CQB tests (increase 1.1 ± 1.8 points; P = 0.044) and the completion times of CQB tests (increase 9.8 ± 7.2 s; P = 0.015) of the CAF trial were significantly better than those of the PL trial. The values of LF, LF/HF, salivary caffeine and α-Amylase concentration in the CAF trial were significantly higher compared to the PL trial (P < 0.05).
CONCLUSIONS: Caffeinated chewing gum may improve military performance and cognitive performance by increasing sympathetic nervous system activity, as indicated by heart rate variability and salivary α-amylase concentration in CAF trials.
TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov ID NCT06638372.
METHODS: Sixteen male serving special forces soldiers (age: 34 ± 7 years; height: 172 ± 4 cm; BMI: 25.4 ± 2.7 kg/m²) completed the caffeinated chewing gum (CAF) trial and the placebo (PL) trial using a randomised crossover experimental design. After chewing the caffeinated chewing gum containing 3 mg·kg- 1 of caffeine (CAF trial) or placebo gum (PL trial), participants completed the cognitive tasks, grip strength, weighted vertical jump and the special forces military performance tests which included rapid-fire test and close-quarters battle (CQB) tests. Before, during, and after the experiment, the heart rate variability and salivary α-amylase were collected.
RESULTS: Grip strength (increase 4.4 ± 7.1 kg; P = 0.037), weighted vertical jump height (increase 1.3 ± 2.1 cm; P = 0.032), cognitive tasks (simple response times, stroop task and visual search reaction time in 20 items) (P < 0.05), shooting scored in rapid-fire test (increase 1.0 ± 2.1 points; P = 0.030), the CQB tests (increase 1.1 ± 1.8 points; P = 0.044) and the completion times of CQB tests (increase 9.8 ± 7.2 s; P = 0.015) of the CAF trial were significantly better than those of the PL trial. The values of LF, LF/HF, salivary caffeine and α-Amylase concentration in the CAF trial were significantly higher compared to the PL trial (P < 0.05).
CONCLUSIONS: Caffeinated chewing gum may improve military performance and cognitive performance by increasing sympathetic nervous system activity, as indicated by heart rate variability and salivary α-amylase concentration in CAF trials.
TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov ID NCT06638372.